Dakovir-C Tablet 60 mg contains Daclatasvir, a direct-acting antiviral (DAA) agent used in the treatment of chronic hepatitis C virus (HCV) infection. Daclatasvir is a highly effective NS5A replication complex inhibitor that plays a key role in suppressing viral replication and reducing viral load when used in combination with other antiviral medicines. Dakovir-C Tablet is an important component of modern, interferon-free hepatitis C treatment regimens.

Daclatasvir works by targeting the NS5A protein of the hepatitis C virus, which is essential for viral RNA replication and assembly. By inhibiting this protein, Dakovir-C Tablet helps stop the virus from multiplying and spreading within the body. When used as part of combination therapy, it significantly improves sustained virologic response (SVR) rates, leading to long-term viral clearance in many patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Indications

Dakovir-C Tablet 60 mg is indicated for:

• Treatment of chronic hepatitis C virus infection

• Use in combination with other antiviral agents such as sofosbuvir, with or without ribavirin

• Management of HCV genotypes as recommended by treatment guidelines

• Patients with compensated liver disease, including cirrhosis, under specialist supervision

Dosage and Administration

The dosage of Dakovir-C Tablet is determined by a physician based on hepatitis C genotype, treatment regimen, liver function, and concurrent medications. The usual recommended dose is 60 mg once daily, taken orally with or without food. The tablet should be swallowed whole with water. Treatment duration typically ranges from 12 to 24 weeks, depending on clinical factors and response to therapy.

Dose adjustments may be required when used with certain medications that affect liver enzymes. Strict adherence to the prescribed regimen is essential to achieve optimal treatment outcomes.

Key Benefits

• Direct-acting antiviral with high efficacy against hepatitis C

• Interferon-free treatment option with improved tolerability

• Helps achieve sustained viral clearance when used in combination therapy

• Once-daily oral dosing for better patient compliance

• Reduces risk of long-term liver complications related to HCV

Precautions and Warnings

Dakovir-C Tablet should be used under specialist medical supervision. It is not recommended as monotherapy and must be used in combination with other antiviral agents. Caution is required in patients with severe liver impairment or those taking medicines that strongly interact with Daclatasvir.

Use during pregnancy is not recommended, especially when used in combination regimens that include ribavirin. Effective contraception should be used as advised by a healthcare professional. Regular monitoring of liver function and viral load is recommended during treatment.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Dakovir-C Tablet is generally well tolerated. Common side effects may include headache, fatigue, nausea, and diarrhea. When used with other antiviral medicines, additional side effects related to combination therapy may occur. Patients should report any persistent or severe symptoms to their healthcare provider.

Storage Conditions

Store Dakovir-C Tablet 60 mg in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children.

Dakovir-C Tablet 60 mg is a clinically proven antiviral therapy that plays a vital role in the effective management of chronic hepatitis C, helping patients achieve long-term viral suppression and improved liver health when used as prescribed.